



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Kinzler and Vogelstein

Serial No. 09/966,724

Filed: October 1, 2001

)
)
)
)
)
)

Examiner: Jon Ashen

Group Art Unit: 1635

Atty. Dkt. No. 01107.00193

For: AMPLIFICATION OF HUMAN MDM2 GENE IN HUMAN TUMORS

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§ 1.97 and 1.98

U.S. Patent and Trademark Office
Customer Service Window
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Sir:

The attached two PTO Forms-1449 list documents for the Examiner's consideration.

Copies of the documents are included. If a fee is required, charge our Deposit Account No. 19-0733.

Respectfully submitted,

Date: 24 February 2006

By: Lisa M. Hemmendinger
Lisa M. Hemmendinger
Registration No. 42,653

Customer No. 22907

Please type a plus sign (+) inside this box →

+



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1

of

2

Complete If Known

Application Number	09/966,724
Filing Date	October 1, 2001
First Named Inventor	Kinzler
Group Art Unit	1635
Examiner Name	Jon Ashen
Attorney Docket Number	001107.00193

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
		6,238,921		Miraglia <i>et al.</i>	May 29, 2001	

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ₆
		Office ³	Number ⁴	Kind Code ⁵ (if known)				

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Bartel <i>et al.</i> , "MDM2 and Its Splice Variant Messenger RNAs: Expression in Tumors and Down-Regulation Using Antisense Oligonucleotides," <i>Mol. Cancer Res.</i> 2, 29-35, January 2004	
		Capoulade <i>et al.</i> , "Apoptosis of tumoral and nontumoral lymphoid cells is induced by both mdm2 and p53 antisense oligodeoxynucleotides," <i>Blood</i> 97, 1043-49, February 15, 2001	
		Chen <i>et al.</i> , "Synergistic activation of p53 by inhibition of MDM2 expression and DNA damage," <i>Proc. Natl. Acad. Sci. USA</i> 95, 195-200, January 1998	
		Fiddler <i>et al.</i> , "Amplification of MDM2 Inhibits MyoD-Mediated Myogenesis," <i>Mol. Cell. Biol.</i> 16, 5048-57, September 1996	
		Goetz <i>et al.</i> , "Requirement for Mdm2 in the Survival Effects of Bcr-Abl and Interleukin 3 in Hematopoietic Cells," <i>Cancer Res.</i> 61, 7635-41, October 15, 2001	
		Sato <i>et al.</i> , "Enhancement of Drug Induced Apoptosis by Antisense Oligodeoxynucleotides Targeted against Mdm2 and p21 ^{WAF1/CIP1} ," <i>Anticancer Research</i> 20, 837-42, 2000	
		Uhlmann & Peyman, "Antisense Oligonucleotides: A New Therapeutic Principle," <i>Chem Rev.</i> 90, 543-84, 1990	
		Wang <i>et al.</i> , "MDM2 oncogene as a target for cancer therapy: An antisense approach," <i>Int. J. Oncol.</i> 15, 653-60, 1999	

Examiner
Signature

Date
Considered

Please type a plus sign (+) inside this box →

+



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2

of

2

Complete if Known

Application Number	09/966,724
Filing Date	October 1, 2001
First Named Inventor	Kinzler
Group Art Unit	1635
Examiner Name	Jon Ashen
Attorney Docket Number	001107.00193

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
		6,238,921		Miraglia <i>et al.</i>	May 29, 2001	

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ₆
		Office ³	Number ⁴	Kind Code ⁵ (if known)				

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Wang <i>et al.</i> , "Antisense Anticancer Oligonucleotide Therapeutics," <i>Current Cancer Drug Targets</i> 1, 177-96, 2001	
		Wang <i>et al.</i> , "Chemosensitization and Radiosensitization of Human Cancer by Antisense Anti-MDM2 Oligonucleotides," <i>Ann. N.Y. Acad. Sci.</i> 1002, 217-35, 2003	
		Zang & Wang, "Antisense Oligonucleotide Inhibitors of MDM2 Oncogene Expression," in <i>Methods in Molecular Medicine 85: Novel Anticancer Drug Protocols</i> , pages 205-22, Buolamwini & Adjei, eds., Humana Press, 2003	

Examiner
Signature

Date
Considered